Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Friday, August 14, 2020 · 523,979,000 Articles · 3+ Million Readers

Global Ion Channel Modulators Strategic Business Report 2019: Market Analysis, Trends, and Forecasts 2015-2022

/EIN News/ -- Dublin, Feb. 20, 2019 (GLOBE NEWSWIRE) -- The "Ion Channel Modulators - Market Analysis, Trends, and Forecasts" report has been added to's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Ion Channel Modulators in US$ Million.

The report profiles 39 companies including many key and niche players such as:

  • Allergan plc (Ireland)
  • AstraZeneca (UK)
  • Bayer HealthCare Pharmaceuticals (Germany)
  • Biogen, Inc. (USA)
  • GlaxoSmithKline Plc. (UK)
  • H. Lundbeck A/S (Denmark)
  • Johnson & Johnson (USA)
  • Novartis AG (Switzerland)
  • Parion Sciences, Inc. (USA)
  • Pfizer, Inc. (USA)
  • Sanofi S.A. (France)

Key Topics Covered:

Ion Channel Modulators
A Receding Market
Current and Future Analysis
Aging Population: Creating Need for More Efficient and Safe Drugs
Competitive Scenario

Ion Channels
A Peek into Their Types, Functional Use and Diversity
Ion Channels
Difficult Drug Targets
Currently Available Ion Channel Modulating Drugs in the Market
Select Ion Channel Modulator Drugs by Mode of Action
Ion Channel Modulators by Therapeutic Indication
Cardiovascular Diseases/ Hypertension
Arrhythmia Treatment
Pain Management
Ion Channel Modulation of Antiemetics
Ion Channel Modulators Find Extensive Use in Neglected Tropical Diseases
Other Therapeutic Areas
Ion Channel Screening Aided by APC
Growing Interest in Outsourcing of Ion Channel Services
Selectivity against Subtypes
Need of the Hour for Na Channel Blockers
Select First Gen Sodium Ion Channel Modulators and Indications
Sodium Channel Subtypes, Specific Tissues and Indications
Strong Potential Na Channel Blockers for Use in Neuropathic Pain
New Trial Questions Nifedipine's Use for Treating Chronic Chilblains

Ion Channel Modulators: An Introduction
Biological Significance of Ion Channels
Ion Channel Modulators as an Option for Treating Diseases
Types of Ion Channels
Voltage-Gated Ion Channels
Extracellular Ligand-gated Ion Channels
Intracellular Ligand-gated Ion Channels

Xenon Pharmaceuticals Begins Phase I Trials on XEN1101 Potassium Channel Opener
AstraZeneca Inks Agreement with Aspen for Residual Rights to its Anesthetics Portfolio
Parion Grants Global Rights for P-321 to Shire
Xenon Adds XEN1101 Potassium Channel Modulator to Its Pipeline
Alvogen Recalls 24 Lots of Nifedipine
Parion Commences Phase II Clinical Trial of P-321
AstraZeneca Sells Rights of Anesthetics to Aspen
AstraZeneca Inks Licensing Deal with CMS
Evotec and Asahi Collaborate for Screening of Ion Channel Targets
Catalyst Merges with Targacept
XRpro Acquires Pfizer's Ion Channel Biology Platform
Vertex and Parion Team Up to Develop ENaC Inhibitors
Biogen Idec Changes Name to Biogen
Biogen Idec Acquires Convergence Pharmaceuticals
Pfizer Wins Court Ruling to Block Generic Versions of Lyrica Upto 2018
Forest Labs Discontinues Namenda 5/10 mg Tablets, Launches Namenda XR
Forest Files Lawsuit against Namenda Generic Manufacturers
Cytocentrics Bioscience Selects Drug Safety Testing Center as its Distributor in Japanese Market
Zalicus Licenses Its Entire Sodium Channel Modulator Program to AnaBios Corporation
EPIRUS Merges with Zalicus



Total Companies Profiled: 39 (including Divisions/Subsidiaries 41)

  • The United States (18)
  • Canada (2)
  • Japan (1)
  • Europe (19)
    • France (2)
    • Germany (2)
    • The United Kingdom (6)
    • Italy (2)
    • Rest of Europe (7)
  • Asia-Pacific (Excluding Japan) (1)

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                             Laura Wood, Senior Press Manager
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Central Nervous System Drugs 


Powered by EIN News

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release